Phibro Animal Health Corp: Form 10-Q for the period ended Mar 31, 2025
Filed with the SEC on May 7, 2025 and accepted by EDGAR at May 7, 2025, 20:16 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2025-01-01 to 2025-03-31 | $347.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2024-07-01 to 2025-03-31 | $917.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2025-01-01 to 2025-03-31 | $243.3m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2024-07-01 to 2025-03-31 | $627.6m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2025-01-01 to 2025-03-31 | $104.6m | us-gaap:GrossProfit |
| Gross profit | 9 months2024-07-01 to 2025-03-31 | $289.9m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months2025-01-01 to 2025-03-31 | $71.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2024-07-01 to 2025-03-31 | $213.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2025-01-01 to 2025-03-31 | $33.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2024-07-01 to 2025-03-31 | $76.7m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2025-01-01 to 2025-03-31 | $9.7m | us-gaap:InterestExpenseNonoperating |
| Interest expense | 9 months2024-07-01 to 2025-03-31 | $28.2m | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months2025-01-01 to 2025-03-31 | $8.8m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2024-07-01 to 2025-03-31 | $13.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2025-01-01 to 2025-03-31 | $20.9m | us-gaap:NetIncomeLoss |
| Net income | 9 months2024-07-01 to 2025-03-31 | $31.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2025-01-01 to 2025-03-31 | $0.51 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2024-07-01 to 2025-03-31 | $0.76 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2025-01-01 to 2025-03-31 | $0.52 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2024-07-01 to 2025-03-31 | $0.77 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2025-01-01 to 2025-03-31 | 40,709,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2024-07-01 to 2025-03-31 | 40,669,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2024-07-01 to 2025-03-31 | $58.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2024-07-01 to 2025-03-31 | $25.2m | us-gaap:PaymentsToAcquireProductiveAssets |
| Dividends paid | 9 months2024-07-01 to 2025-03-31 | $14.6m | us-gaap:PaymentsOfDividendsCommonStock |
| Cash and equivalents | At period end2025-03-31 | $60.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-03-31 | $776.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-03-31 | $1.32bn | us-gaap:Assets |
| Current liabilities | At period end2025-03-31 | $266.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-03-31 | $1.05bn | us-gaap:Liabilities |
| Long-term debt | At period end2025-03-31 | $619.2m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2025-03-31 | $16.3m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2025-03-31 | $266.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001558370-25-006746. Last ingested by Listed: Oct 24, 2026, 15:03 ET. Listed shows no prices and gives no investment advice.